Esphera SynBio Closes Seed Financing Round to Develop Nanomedicine Vaccines for Cancer and Infectious Disease
Summary
The financing builds on the Companys advanced R&D activities and proceeds are directed at the identification of an initial cancer vaccine clinical candidate and general corporate purposes. Seed investors GKCC and FACIT supported the financing.Using synthetic biology, Esphera produces engineered exosomes through the expression of proprietary transgenes that serve as nanomedicines. "This financing enables us to validate our vaccine platform and advance a potential best-in-class therapy for patients living with cancer," said Dr. Brian Lichty, co-founder and CEO of Esphera. "Espheras innovative platform produces therapeutic nanomedicines that can act as powerful immunostimulants, delivering customized antigenic payloads to stimulate robust immune responses. These technologies utilize synthetic biology approaches to modify cells through the expression of proprietary transgenes causing the production of engineered exosomes that serve as nanomedicines for the treatment and prevention of human disease.